Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) announced that its wholly-owned subsidiary, Zhejiang Saimer Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for the drug BIOS2242 oral solution, which is aimed at treating cerebral ischemic diseases [1] Group 1: Product Development - The BIOS2242 oral solution is designed to address treatment challenges in conditions such as stroke, cerebral ischemia, and cerebral infarction, which can lead to symptoms like coma, consciousness disorders, paralysis, and limb numbness [1] - Traditional oral solid dosage forms, such as tablets and capsules, are often limited in use due to difficulties in swallowing or oral intake by patients [1] - The oral solution format provides a better medication option, simplifying the administration process and improving the feasibility and accuracy of drug intake [1] Group 2: Market Position - Currently, there are no approved products in the domestic and international markets that are equivalent to BIOS2242 oral solution [1]
百诚医药(301096.SZ)：子公司申报的BIOS2242口服溶液获得临床试验批准通知书